PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of molvisLink to Publisher's site
 
Mol Vis. 2010; 16: 2273–2278.
Published online 2010 November 3.
PMCID: PMC2994334

Lack of association of CFD polymorphisms with advanced age-related macular degeneration

Abstract

Purpose

Age-related macular degeneration (AMD) is the most common cause of irreversible central vision loss worldwide. Research has linked AMD susceptibility with dysregulation of the complement cascade. Typically, complement factor H (CFH), complement factor B (CFB), complement component 2 (C2), and complement component 3 (C3) are associated with AMD. In this paper, we investigated the association between complement factor D (CFD), another factor of the complement system, and advanced AMD in a Caucasian population.

Methods

Six single nucleotide polymorphisms (SNPs), rs1683564, rs35186399, rs1683563, rs3826945, rs34337649, and rs1651896, across the region covering CFD, were chosen for this study. One hundred and seventy-eight patients with advanced AMD and 161 age-matched normal controls were genotyped. Potential positive signals were further tested in another independent 445 advanced AMD patients and 190 controls. χ2 tests were performed to compare the allele frequencies between case and control groups.

Results

None of the six SNPs of CFD was found to be significantly associated with advanced AMD in our study.

Conclusions

Our findings suggest that CFD may not play a major role in the genetic susceptibility to AMD because no association was found between the six SNPs analyzed in the CFD region and advanced AMD.

Introduction

Age-related macular degeneration (AMD) is the most common cause of irreversible central vision loss worldwide [1]. It can be divided into early and advanced (late) forms. Early AMD is characterized by the presence of drusen or pigmentary abnormalities in the retinal pigment epithelium (RPE), while advanced AMD includes two clinical types—geographic atrophy of the RPE (dry AMD) and choroidal neovascularization (wet AMD). Age-related macular degeneration is a complex disease caused by the combination of genetic predisposition and environmental factors [2-4]. The inheritance of AMD is polygenic and multifactorial: race, age, smoking, body mass, and body mass index have all been associated with AMD [2,5-9]. In the past five years, significant progress has been made in our understanding of AMD genetics through studies that identified specific single nucleotide polymorphisms (SNPs) significantly associated with AMD. The discovery of the strongest associations of AMD with the variants of complement factor H (CFH; OMIM 134370) [10-13] and ARMS2/HTRA1 (age-related maculopathy susceptibility 2, OMIM 611313; the high temperature requirement factor A1, OMIM: 602194) [14-17] has led to new hypotheses regarding the pathogenesis of this disease. CFH is primarily associated with the formation of drusen that often characterizes both types of advanced AMD in Caucasian populations, whereas ARMS2/HTRA1 is mainly associated with wet AMD [18]. Other than these two major loci, three other members of the complement system, complement component 2 (C2; OMIM 217000), complement component 3 (C3; OMIM 120700), and complement factor B (CFB; OMIM 138470), were also found to be associated with AMD [10,19-21]. Most of these genes are complement pathway-associated genes, with the products participating in the alternative complement pathway and playing important roles in the complement system. Many studies have provided evidence that the complement system is involved in the pathogenesis of AMD and may have a pivotal effect on the formation and development of the disease [13,22-24]. However, the specific role of the complement system in the etiology of AMD is difficult to elucidate, and questions remain as to whether other components from this system are associated with AMD.

Complement factor D (CFD) is a protein of the trypsin family encoded by the CFD gene (OMIM 134350) and is involved in the alternative complement pathway of the complement system [25,26]. CFD is unique among serine proteases in that it requires neither enzymatic cleavage for expression of proteolytic activity nor inactivation by a serpin for its control [27]. It is best known for its role in humoral suppression of infectious agents and has a high level of expression in fat, suggesting a role for adipose tissue in immune system biology (CFD). In this study, we investigated the association of CFD with advanced AMD in a Caucasian population.

Methods

Subjects and clinical diagnosis

This study was approved by the Institutional Review Board of the University of California, San Diego. Informed consent was signed by all subjects before participation in the study. One hundred and seventy-eight nonfamilial advanced AMD patients and 161 age-matched normal controls (60 years or older with no drusen or RPE changes) as well as an independent replication cohort with 445 nonfamilial advanced AMD patients and 190 age-matched normal controls were recruited using the standard ophthalmic examination protocol. Grading was performed using a standard grid classification suggested by the International Age-related Maculopathy (ARM) Epidemiological Study Group for the age-related maculopathy and age-related macular degeneration group [28]. All the participants were Caucasian.

Genotyping

Six SNPs, rs1683564, rs35186399, rs1683563, rs3826945, rs34337649, and rs1651896 at the CFD locus were chosen, which were either tag SNPs or those that might affect the function of CFD (Figure 1). A Caucasian cohort of 178 advanced AMD patients was genotyped and allele frequencies were compared with 161 age- and ethnicity-matched normal controls by laboratory personnel blinded to the case/control status. Potential positive findings were tested for replication in an independent cohort of 445 advanced AMD patients and 190 normal controls.

Figure 1
Six single nucleotide polymorphisms (SNPs) on complement factor D (CFD). Shown is the corresponding location of each SNP on CFD (chromosome:19; location:19p13.3) that was chosen in this study.

Genotypes of six SNPs were achieved by primer extension of multiplex PCR products followed with a SNaPshot using an ABI 3100 genetic analyzer (Applied Biosystems, Foster City, CA).

Statistical analysis

Deviation from Hardy–Weinberg equilibrium was assessed, with a statistical significance level of 0.01. A chi-square test was performed to assess evidence for association. The statistical significance level was adjusted by Bonferroni correction. Linkage disequilibrium (LD) patterns and haplotype blocks were defined using Haploview 4.1.

Results

We genotyped six SNPs that tag the majority of CFD haplotypes and investigated allelic association with AMD. Four SNPs, rs1683564, rs35186399, rs1683563, and rs3826945, located either at the promoter region, exon, or intron of CFD, exhibited no association with advanced AMD in our study population. The SNP rs34337649, in exon 5 of CFD, showed no polymorphisms in our data (Table 1).

Table 1
Association between 5 single nucleotide polymorphisms (SNPs) on complement factor D (CFD) and advanced age related macular degeneration (AMD)

Of the six SNPs, rs1651896, which is located at the 3′ region of CFD, was found to be marginally associated with advanced AMD (P(allelic)=0.07, risk allele A: 37.4% in cases versus 30.7% in controls) in a Caucasian cohort of 178 advanced AMD cases and 161 normal controls. The result was further investigated in an independent replication cohort of 445 advanced AMD patients and 190 controls. No further significant association was observed for either the replication cohort (P(allelic)=0.882, risk allele A: 37.2% in cases versus 37.6% in controls) or the combined cohort (P(allelic)=0.223, risk allele A: 37.2% in cases versus 34.5% in controls, Table 2).

Table 2
Association between complement factor D (CFD) single nucleotide polymorphism (SNP) rs1651896 and advanced age related macular degeneration (AMD) in the discovery, replication and combination cohorts

Linkage disequilibrium patterns and haplotype blocks were defined by combining the six SNPs (Figure 2). No significant association was found between the haplotypes and AMD phenotypes. The SNP rs34337649 was not shown in the plot because it was not a detected polymorphism in our data set.

Figure 2
Linkage disequilibrium (LD) plot of six single nucleotide polymorphisms (SNPs) on complement factor D (CFD). The physical position of each SNP is shown above the plot. Darker shades of red indicate higher values of the LD coefficient (D'). The numbers ...

Discussion

The alternative complement pathway is one of three distinct complement pathways and is important in the clearance and recognition of pathogens in the absence of antibodies [29] (Figure 3). It is triggered by spontaneous C3 hydrolysis to form C3a and C3b, which makes C3b capable of binding to a pathogenic membrane surface. After binding with an activator membrane, C3b is bound by CFB to form C3bB. Complement factor H acts as one of the primary regulators by inhibiting the binding of CFB to C3b and also by degrading C3b. In the presence of CFD, C3bB is cleaved into C3bBa and C3bBb (C3 convertase). After hydrolysis of C3, C3 convertase and C3b become C3bBbC3b, which cleaves C5 into C5a and C5b. A membrane attack complex (MAC) is formed through subsequent reactions, which inserts into the cell membrane and initiates cell lysis [18,30,31]. In this pathway, CFB and CFD are involved in the activation and amplification loop, whereas CFH is a fluid phase inhibitor. To keep the complement activity under control, the competition between CFH and CFB binding to C3b on the host or pathogen cells needs to be tightly regulated. How this control is achieved is not completely clear [18].

Figure 3
The alternative complement pathway. The principal components of the alternative complement pathway from C3 to the stage of membrane attack complex (MAC) formation are shown in detail. Complement factor H (CFH) with the dotted arrow acts as an inhibiting ...

Compared with other complement factors, CFH, C3, and CFB have been associated with AMD in many independent studies. However, the exact role they play in the pathogenesis of AMD and whether their effects are mediated through the complement system or through another pathway is poorly understood. Previously, CFD was studied using a CFD −/− mouse model, with the conclusion that eliminating the alternative pathway was neuroprotective and reduced photoreceptor susceptibility to light-induced damage [25]. Contrary to this finding, no significant association between CFD SNPs and advanced AMD was found in this study. Due to the dearth of information about the relationship between CFD and AMD, further research in other populations may be warranted. Our results suggest it is unlikely that CFD is a major functional candidate gene conferring risk for AMD. However, due to the relatively small sample size, this study has limited power to detect minor effects. Extended cohorts will be needed to confirm the genetic role of CFD. Future research should also focus on a comprehensive understanding of genetic variants throughout all pathways of the complement system. By identifying high risk variants and improving our understanding of the complement system, early intervention for patients at risk of developing AMD and novel gene-based treatments may become a reality.

Acknowledgments

We thank all the participating AMD patients and their families. K.Z. is supported by grants from NIH, VA Merit Award, Foundation Fighting Blindness, the Macula Vision Research Foundation, Ruth and Milton Steinbach Fund, Research to Prevent Blindness, BWF Clinical Scientist Award in Translational Research. K.Z. has full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

References

1. Chappelow AV, Kaiser PK. Neovascular age-related macular degeneration: potential therapies. Drugs. 2008;68:1029–36. [PubMed]
2. Montezuma SR, Sobrin L, Seddon JM. Review of genetics in age related macular degeneration. Semin Ophthalmol. 2007;22:229–40. [PubMed]
3. Patel N, Adewoyin T, Chong NV. Age-related macular degeneration: a perspective on genetic studies. Eye (Lond) 2008;22:768–76. [PubMed]
4. Khan JC, Thurlby DA, Shahid H, Clayton DG, Yates JR, Bradley M, Moore AT, Bird AC, Genetic Factors in AMD Study. Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol. 2006;90:75–80. [PMC free article] [PubMed]
5. Bressler SB, Munoz B, Solomon SD, West SK. Racial differences in the prevalence of age-related macular degeneration: the Salisbury Eye Evaluation (SEE) Project. Arch Ophthalmol. 2008;126:241–5. [PubMed]
6. Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL., 3rd Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology. 2005;112:533–9. [PMC free article] [PubMed]
7. Klein R, Klein BE, Tomany SC, Cruickshanks KJ. The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam eye study. Ophthalmology. 2003;110:636–43. [PubMed]
8. Seddon JM, Cote J, Davis N, Rosner B. Progression of age-related macular degeneration: association with body mass index, waist circumference, and waist-hip ratio. Arch Ophthalmol. 2003;121:785–92. [PubMed]
9. van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT. Epidemiology of age-related maculopathy: a review. Eur J Epidemiol. 2003;18:845–54. [PubMed]
10. Katta S, Kaur I, Chakrabarti S. The molecular genetic basis of age-related macular degeneration: an overview. J Genet. 2009;88:425–49. [PubMed]
11. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI, Hageman JL, Stockman HA, Borchardt JD, Gehrs KM, Smith RJ, Silvestri G, Russell SR, Klaver CC, Barbazetto I, Chang S, Yannuzzi LA, Barile GR, Merriam JC, Smith RT, Olsh AK, Bergeron J, Zernant J, Merriam JE, Gold B, Dean M, Allikmets R. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA. 2005;102:7227–32. [PubMed]
12. Brantley MA, Jr, Fang AM, King JM, Tewari A, Kymes SM, Shiels A. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology. 2007;114:2168–73. [PubMed]
13. Anderson DH, Radeke MJ, Gallo NB, Chapin EA, Johnson PT, Curletti CR, Hancox LS, Hu J, Ebright JN, Malek G, Hauser MA, Rickman CB, Bok D, Hageman GS, Johnson LV. The pivotal role of the complement system in aging and age-related macular degeneration: Hypothesis re-visited. Prog Retin Eye Res. 2010;29:95–112. [PubMed]
14. Yang Z, Camp NJ, Sun H, Tong Z, Gibbs D, Cameron DJ, Chen H, Zhao Y, Pearson E, Li X, Chien J, Dewan A, Harmon J, Bernstein PS, Shridhar V, Zabriskie NA, Hoh J, Howes K, Zhang K. A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science. 2006;314:992–3. [PubMed]
15. Dewan A, Liu M, Hartman S, Zhang SS, Liu DT, Zhao C, Tam PO, Chan WM, Lam DS, Snyder M, Barnstable C, Pang CP, Hoh J. HTRA1 promoter polymorphism in wet age-related macular degeneration. Science. 2006;314:989–92. [PubMed]
16. Andreoli MT, Morrison MA, Kim BJ, Chen L, Adams SM, Miller JW, DeAngelis MM, Kim IK. Comprehensive analysis of complement factor H and LOC387715/ARMS2/HTRA1 variants with respect to phenotype in advanced age-related macular degeneration. Am J Ophthalmol. 2009;148:869–74. [PMC free article] [PubMed]
17. Cameron DJ, Yang Z, Gibbs D, Chen H, Kaminoh Y, Jorgensen A, Zeng J, Luo L, Brinton E, Brinton G, Brand JM, Bernstein PS, Zabriskie NA, Tang S, Constantine R, Tong Z, Zhang K. HTRA1 variant confers similar risks to geographic atrophy and neovascular age-related macular degeneration. Cell Cycle. 2007;6:1122–5. [PubMed]
18. DeWan A, Bracken MB, Hoh J. Two genetic pathways for age-related macular degeneration. Curr Opin Genet Dev. 2007;17:228–33. [PubMed]
19. Seddon JM, Reynolds R, Maller J, Fagerness JA, Daly MJ, Rosner B. Prediction model for prevalence and incidence of advanced age-related macular degeneration based on genetic, demographic, and environmental variables. Invest Ophthalmol Vis Sci. 2009;50:2044–53. [PubMed]
20. Kaur I, Katta S, Reddy RK, Narayanan R, Mathai A, Majji AB, Chakrabarti S. The involvement of complement factor B and complement component C2 in an Indian cohort with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2010;51:59–63. [PubMed]
21. Despriet DD, van Duijn CM, Oostra BA, Uitterlinden AG, Hofman A, Wright AF, ten Brink JB, Bakker A, de Jong PT, Vingerling JR, Bergen AA, Klaver CC. Complement component C3 and risk of age-related macular degeneration. Ophthalmology. 2009;116:474–80. [PubMed]
22. Zanke B, Hawken S, Carter R, Chow D. A genetic approach to stratification of risk for age-related macular degeneration. Can J Ophthalmol. 2010;45:22–7. [PubMed]
23. Nussenblatt RB, Liu B, Li Z. Age-related macular degeneration: an immunologically driven disease. Curr Opin Investig Drugs. 2009;10:434–42. [PubMed]
24. Gehrs KM, Jackson JR, Brown EN, Allikmets R, Hageman GS. Complement, age-related macular degeneration and a vision of the future. Arch Ophthalmol. 2010;128:349–58. [PubMed]
25. Rohrer B, Guo Y, Kunchithapautham K, Gilkeson GS. Eliminating complement factor D reduces photoreceptor susceptibility to light-induced damage. Invest Ophthalmol Vis Sci. 2007;48:5282–9. [PubMed]
26. Sprong T, Roos D, Weemaes C, Neeleman C, Geesing CL, Mollnes TE, van Deuren M. Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections. Blood. 2006;107:4865–70. [PubMed]
27. Volanakis JE, Narayana SV. Complement factor D, a novel serine protease. Protein Sci. 1996;5:553–64. [PubMed]
28. Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, de Jong PT, Klaver CC, Klein BE, Klein R, Mitchell P, Sarks JP, Sarks SH, Soubrane G, Taylor HR, Vingerling JR. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol. 1995;39:367–74. [PubMed]
29. Stahl GL, Xu Y, Hao L, Miller M, Buras JA, Fung M, Zhao H. Role for the alternative complement pathway in ischemia/reperfusion injury. Am J Pathol. 2003;162:449–55. [PubMed]
30. Hecker LA, Edwards AO, Ryu E, Tosakulwong N, Baratz KH, Brown WL, Charbel Issa P, Scholl HP, Pollok-Kopp B, Schmid-Kubista KE, Bailey KR, Oppermann M. Genetic control of the alternative pathway of complement in humans and age-related macular degeneration. Hum Mol Genet. 2010;19:209–15. [PMC free article] [PubMed]
31. Scholl HP, Charbel Issa P, Walier M, Janzer S, Pollok-Kopp B, Börncke F, Fritsche LG, Chong NV, Fimmers R, Wienker T, Holz FG, Weber BH, Oppermann M. Systemic complement activation in age-related macular degeneration. PLoS ONE. 2008;3:e2593. [PMC free article] [PubMed]

Articles from Molecular Vision are provided here courtesy of Emory University and the Zhongshan Ophthalmic Center, Sun Yat-sen University, P.R. China